恩扎鲁胺
卡巴齐塔塞尔
阿比曲酮
前列腺癌
医学
多西紫杉醇
肿瘤科
内科学
癌症
雄激素剥夺疗法
雄激素受体
作者
Ronald de Wit,Johann S. de Bono,Cora N. Sternberg,Karim Fizazi,Bertrand Tombal,Christian Wülfing,Gero Kramer,Jean‐Christophe Eymard,Aristotelis Bamias,Joan Carles,Roberto Iacovelli,Bohuslav Melichar,Ásgerður Sverrisdóttir,Christine Théodore,Susan Feyerabend,Carole Hélissey,Ayse Ӧzatılgan,Christine Geffriaud-Ricouard,Daniel Castellano
标识
DOI：10.1056/nejmoa1911206
摘要
The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
昏睡的蟠桃
柯亦云
哈基米德
SYLH
乐乐乐乐乐乐
如意草丛
亚特兰蒂斯
LaTeXer
yydragen
比比谁的速度快
fang
嘿嘿
Rondab
yx_cheng
CAOHOU
快乐的胖子
七月流火
pluto
老阎
nanaki
皖公网安备34019202002308
